Share: Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications;
Gilead to Receive Royalties on European Sales Starting in 2024 Galapagos to Assume Responsibility for Majority of Ongoing Clinical Trials Gilead will Pay Galapagos €160 million to Support Ongoing Development and Accelerated Commercial Buildout in EU
Galapagos webcast presentation tomorrow, 16 December 2020, at 14:00 CET / 8 AM ET, +32 2 793 38 47, code 7689939
Foster City, Calif., and Mechelen, Belgium, December 15, 2020, 22.15 CET; regulated information – Gilead Sciences, Inc. (NASDAQ:GILD) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that the companies have agreed to amend their existing arrangement for the commercialization and development of Jyseleca (filgotinib). This announcement follo
Galapagos NV: Gilead and Galapagos announce New Commercialization and Development Agreement for Jyseleca (filgotinib) Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications;
Gilead to Receive Royalties on European Sales Starting in 2024 Galapagos to Assume Responsibility for Majority of Ongoing Clinical Trials Gilead will Pay Galapagos €160 million to Support Ongoing Development and Accelerated Commercial Buildout in EU
Galapagos webcast presentation tomorrow, 16 December 2020, at 14:00 CET / 8 AM ET,
Message :
Required fields Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications;
Gilead to Receive Royalties on European Sales Starting in 2024 Galapagos to Assume Responsibility for Majority of Ongoing Clinical Trials Gilead will Pay Galapagos €160 million to Support Ongoing Development and Accelerated Commercial Buildout in EU
Galapagos webcast presentation tomorrow, 16 December 2020, at 14:00 CET / 8 AM ET, +32 2 793 38 47, code 7689939
Foster City, Calif., and Mechelen, Belgium, December 15, 2020, 22.15 CET; regulated information – Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the companies have agreed to amend their existing arrangement for the commercialization and development of Jyseleca (filgotinib). This a
Gilead and Galapagos announce New Commercialization and Development Agreement for Jyseleca® (filgotinib) Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications;
Gilead to Receive Royalties on European Sales Starting in 2024 Galapagos to Assume Responsibility for Majority of Ongoing Clinical Trials Gilead will Pay Galapagos €160 million to Support Ongoing Development and Accelerated Commercial Buildout in EU
Galapagos webcast presentation tomorrow, 16 December 2020, at 14:00 CET / 8 AM ET,
Gilead and Galapagos announce New Commercialization and Development Agreement for Jyseleca(R) (filgotinib) marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.